Literature DB >> 14963348

Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists.

M A Zurkirchen1, T Sulser, A Gaspert, D Hauri.   

Abstract

INTRODUCTION: As even experienced urologists have a high percentage of persisting carcinoma after transurethral bladder tumour resection (TUR-B) the importance of a routine second resection in the management of transitional cell carcinoma (TCC) of the bladder is defined. PATIENTS AND METHODS: The medical records of all patients treated with TUR-B at our institution between January 1989 and September 2000 were reviewed. 214 patients with pTa and pT1 carcinoma undergoing a second resection 4-6 weeks later were included in the analysis. The rate of persisting carcinoma in the second resection was compared to the actual tumour stage and grade, the patient's age, sex and the experience of the urologist performing the resection.
RESULTS: Of the 214 patients 99 had pTa and 115 pT1 carcinoma. The rate of persisting tumour in the second resection was 27% in pTa and 37% in pT1 carcinoma. This rate was independent of the patient's age and sex. Urologists in training had an equally low rate of persisting carcinoma in the second resection compared to senior urologists (p = 0.08).
CONCLUSIONS: Routine second resection of superficial transitional cell carcinoma of the bladder should be part of the treatment even in larger operative experience. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 14963348     DOI: 10.1159/000075961

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  21 in total

Review 1.  Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer.

Authors:  Miguel Ramírez-Backhaus; José Domínguez-Escrig; Argimiro Collado; José Rubio-Briones; Eduardo Solsona
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

2.  Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.

Authors:  Takuya Koie; Chikara Ohyama; Shogo Hosogoe; Hayato Yamamoto; Atsushi Imai; Shingo Hatakeyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Tohru Yoneyama; Yuki Tobisawa; Kazuyuki Mori
Journal:  Int Urol Nephrol       Date:  2015-07-07       Impact factor: 2.370

3.  The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.

Authors:  Askin Eroglu; Rahmi Gokhan Ekin; Gokhan Koc; Rauf Taner Divrik
Journal:  Int J Clin Oncol       Date:  2019-11-23       Impact factor: 3.402

4.  Update on the management of non-muscle invasive bladder cancer.

Authors:  Saad Aldousari; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

5.  Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta.

Authors:  Geoffrey T Gotto; Melissa A Shea-Budgell; J Dean Ruether
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

Review 6.  Approaching the optimal transurethral resection of a bladder tumor.

Authors:  Michael Jurewicz; Mark S Soloway
Journal:  Turk J Urol       Date:  2014-06

7.  [Predictors for presence of residual tumor in follow-up transurethral resection of bladder tumors: single center results].

Authors:  J Hartinger; R Häußermann; P Olbert; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

8.  Preliminary Porcine In Vivo Evaluation of a Telerobotic System for Transurethral Bladder Tumor Resection and Surveillance.

Authors:  Nima Sarli; Giuseppe Del Giudice; Smita De; Mary S Dietrich; Stanley Duke Herrell; Nabil Simaan
Journal:  J Endourol       Date:  2018-06       Impact factor: 2.942

Review 9.  Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.

Authors:  Siamak Daneshmand; Anne K Schuckman; Bernard H Bochner; Michael S Cookson; Tracy M Downs; Leonard G Gomella; H Barton Grossman; Ashish M Kamat; Badrinath R Konety; Cheryl T Lee; Kamal S Pohar; Raj S Pruthi; Matthew J Resnick; Norm D Smith; J Alfred Witjes; Mark P Schoenberg; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2014-09-23       Impact factor: 14.432

10.  Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer.

Authors:  Yusuke Kimura; Masashi Honda; Shuichi Morizane; Katsuya Hikita; Tadahiro Isoyama; Koji Ono; Tsutomu Koumi; Chihiro Takahashi; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2019-06-20       Impact factor: 1.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.